BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase (collagenase clostridium histolyticum or CCH) is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren’s contracture and for Peyronie's disease in Canada, Europe and Australia.

Endo is partnered with Paladin Labs, Sobi, Actelion and Asahi Kasei for Dupuytren's contracture and/or Peyronie's disease outside of the U.S.

The XIAFLEX /CCH research and development pipeline includes several additional promising indications. Endo is opted-in to manage the development for cellulite, adhesive capsulitis, human and canine lipomas, lateral hip fat and plantar fibromatosis. Endo reported top-line results from two Phase 3 clinical trials of CCH for the treatment of cellulite in November 2018 with additional data presentations in May and June 2019. A BLA submission for CCH for the treatment of cellulite is expected in the second half of 2019 and a commercial launch expected in the second half of 2020. BioSpecifics is managing the development of CCH for the treatment of uterine fibroids. Positive results from the Phase 1 clinical trial were reported in March 2019 at the 66th Annual Meeting for the Society for Reproductive Investigation and additional data from the Phase 1 trial is expected to be presented at an upcoming medical meeting in the second half of 2019.